BACKGROUND: Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment. Gemcitabine, a nucleoside analogue, is active against a range of solid tumors. This phase II study investigated the activity of single-agent gemcitabine in patients with recurrent ovarian cancer. PATIENTS AND METHODS: Thirty-eight patients with FIGO stage III (34%) or IV (64%) ovarian cancer who were previously treated with platinum-containing regimens were enrolled. Patients received 1200 mg/m2 gemcitabine on days 1, 8 and 15 of a 28-day cycle. RESULTS: Patients completed an average of 3.6 cycles. Two complete and three partial responses were seen in 36 evaluable patients, for an overall response rate of 13.9% (95% CI: 4.7%-29.5%). The median survival time was 6.7 months. Toxicities were generally mild. The most common were grade 3-4 neutropenia and grade 3 leukopenia reported in 23.7% and 10.5% of patients, respectively. One patient had grade 4 pulmonary toxicity. CONCLUSION: Single-agent gemcitabine is active and well tolerated in patients with recurrent ovarian cancer.
BACKGROUND: Most patients with advanced ovarian cancer will relapse following platinum-based combination chemotherapy and be considered for second-line treatment. Gemcitabine, a nucleoside analogue, is active against a range of solid tumors. This phase II study investigated the activity of single-agent gemcitabine in patients with recurrent ovarian cancer. PATIENTS AND METHODS: Thirty-eight patients with FIGO stage III (34%) or IV (64%) ovarian cancer who were previously treated with platinum-containing regimens were enrolled. Patients received 1200 mg/m2 gemcitabine on days 1, 8 and 15 of a 28-day cycle. RESULTS:Patients completed an average of 3.6 cycles. Two complete and three partial responses were seen in 36 evaluable patients, for an overall response rate of 13.9% (95% CI: 4.7%-29.5%). The median survival time was 6.7 months. Toxicities were generally mild. The most common were grade 3-4 neutropenia and grade 3 leukopenia reported in 23.7% and 10.5% of patients, respectively. One patient had grade 4 pulmonary toxicity. CONCLUSION: Single-agent gemcitabine is active and well tolerated in patients with recurrent ovarian cancer.
Authors: Petronella O Witteveen; Koen J C van der Mijn; Maartje Los; Roelien H Kronemeijer; Gerard Groenewegen; Emile E Voest Journal: Neoplasia Date: 2010-11 Impact factor: 5.715
Authors: Nadim Bou Zgheib; Yin Xiong; Douglas C Marchion; Elona Bicaku; Hye Sook Chon; Xiaomang Ba Stickles; Entidhar Al Sawah; Patricia L Judson; Ardeshir Hakam; Jesus Gonzalez-Bosquet; Robert M Wenham; Sachin M Apte; Christopher L Cubitt; Dung Tsa Chen; Johnathan M Lancaster Journal: Int J Oncol Date: 2012-04-26 Impact factor: 5.650
Authors: L S Hofstra; A M Bos; E G de Vries; A G van der Zee; J H Beijnen; H Rosing; N H Mulder; J G Aalders; P H Willemse Journal: Br J Cancer Date: 2001-11-30 Impact factor: 7.640
Authors: M Harries; C Moss; T Perren; M Gore; G Hall; M Everard; R A'Hern; I Gibbens; A Jenkins; R Shah; C Cole; O Pizzada; S Kaye Journal: Br J Cancer Date: 2004-08-16 Impact factor: 7.640